<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/tm239317-2_8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/0001104659-23-033054-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 2.02 Item 8.01 Item 9.01

Acurx Pharmaceuticals Inc

Analyst Summary:

Acurx Pharmaceuticals, a clinical stage biopharmaceutical company, announced its Q4 and full-year 2022 results, reporting that it ended the year with $9.1 million cash on hand compared to $13.0 million as of December 31,2021. The increase in losses was due primarily to Phase 2b trial related costs. The CEO David P. Luci and CFO Robert G. Shawah will host a conference call to discuss results and provide a business update. Acurx is currently enrolling Phase 2b clinical trial patients with CDI, these patients will be enrolled in a 1:1 ratio to either ibezapolstat or vancomycin over 10 days (see https://clinicaltrials.gov/ct2/show/NCT04247542). Phase 2a data showed complete eradication of C. difficile by day three of treatment with ibezapolstat, as well as an increase in the concentration of secondary bile acids during and following ibezapolstat therapy known to correlate with colonization resistance against C. difficile. While Acurx's cash on hand has slightly decreased, their research development and business goals are moving forward, and the current market size of C. difficile approaches 500,000 infections annually in the U.S.

$ACXP Reports Q4 2022 and Full-Year Financial Results

Announcement: ACXP 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1736243/000155837023003929/acxp-20221231x10k.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1736243/000155837023003929/0001558370-23-003929-index.htm>Original filing index</a>
                    </div>

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Part 1: Analysis of Performance

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to treat infections caused by antibiotic-resistant pathogens. The company's lead antibiotic candidate, ibezapolstat, has a novel mechanism of action targeting the Pol IIIC enzyme, which is necessary for the replication of DNA in certain Gram-positive bacterial species. The company has clinically validated the bacterial target and has completed a Phase 2a clinical trial to treat patients with CDI. The early termination of the trial was based on the recommendation of the Scientific Advisory Board, which unanimously supported it after the fulfillment of the treatment goals of eliminating the infection with an acceptable adverse event profile.

The company commenced enrollment in a Phase 2b clinical trial of oral ibezapolstat compared to oral vancomycin, a standard of care to treat CDI, on December 3, 2021. The Phase 2a clinical trial's results are very encouraging as all 10 patients enrolled in the trial met the primary and secondary efficacy endpoints, with no treatment-related SAEs reported. These results represent the first-ever clinical data showing Pol IIIC's potential as a therapeutically relevant antibacterial target. The company believes that its approach to developing a new class of antibiotic candidates that block Pol IIIC is the way forward to provide a solution to the global crisis of antimicrobial resistance, which will leave us defenseless against infections that can be treated easily today.

In terms of financial performance, the company had cash of $9.1 million as of December 31, 2022. The company intends to "de-risk" this new class of antibiotics through its drug development activities and potentially partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization. While the company's financial condition is not yet strong, the positive results from the Phase 2a clinical trial and the commencement of the Phase 2b clinical trial are the early indicators of a successful future.

Part 2: Forward-Looking Analysis

Acurx Pharmaceuticals, Inc. is focused on developing a new class of antibiotics to treat infections caused by antibiotic-resistant pathogens. The global crisis of antimicrobial resistance is a significant issue that needs to be addressed, and the company's strategy of developing a new class of antibiotic candidates that block Pol IIIC is a game-changer. The company's lead antibiotic candidate, ibezapolstat, has already shown promising results, and the Phase 2b clinical trial that commenced enrollment on December 3, 2021, will provide a better picture of the drug's potential.

The company has a proactive approach to de-risking its new class of antibiotics through its drug development activities and potentially partnering with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization. The company's early stage pipeline of antibiotic product candidates with the same previously unexploited mechanism of action, including ACX-375C, has established proof of concept in animal studies. The promising results from the Phase 2a clinical trial and the commencement of the Phase 2b clinical trial provide the company with a significant boost and a tremendous competitive advantage in the biopharmaceutical industry.

In conclusion, the company's focus on developing a new class of antibiotic candidates that block Pol IIIC is a game-changer in addressing the global crisis of antimicrobial resistance. The company's early success and proactive approach to de-risking its new class of antibiotics through its drug development activities and potentially partnering with a fully-integrated pharmaceutical company give confidence that the company has a bright future. The commencement of the Phase 2b clinical trial is expected to further strengthen the company's competitive position in the biopharmaceutical industry.

Acurx's Antibiotics Prove Effective in Clinical Trials

Announcement: ACXP 10-K Annual Report

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/tm2229909d1_8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 2.02 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000155837022017408/acxp-20220930x10q.htm>Download 10-Q Quarterly Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000155837022017408/0001558370-22-017408-index.htm>Original filing index</a>
                        </div>

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Announcement: ACXP 10-Q Quarterly Report

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/tm2223469d1_8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000110465922091225/0001104659-22-091225-index.htm>Original filing index</a>
                        </div>

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000141057822002396/acxp-20220630x10q.htm>Download 10-Q Quarterly Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1736243/000141057822002396/0001410578-22-002396-index.htm>Original filing index</a>
                        </div>